Tysabri feels the heat
Executive Summary
Safety evaluation of patients taking Biogen Idec/Elan's multiple sclerosis product Tysabri (natalizumab) remains on track to be completed by "late summer," Elan says. Following a Boston Globe report of a potential fourth case of progressive multifocal leukoencephalopathy, Elan emphasized that there have been only three confirmed cases and two fatalities. In May, FDA said that it will weigh the opinion of patient groups in deciding whether Tysabri should return to market (1"The Pink Sheet" May 16, 2005, p. 12)...